Efficacy and Tolerability of Zonisamide for Alcohol Use Disorder
- 18 September 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
Abstract
Purpose: Zonisamide, an anticonvulsant with GABAergic and glutamatergic effects, has been investigated as a treatment for alcohol use disorder (AUD), but its efficacy and tolerability remain uncertain. This systematic review and meta-analysis synthesizes evidence from randomized controlled trials evaluating zonisamide for AUD. Procedures: We searched MEDLINE, Embase, PsycINFO, Scopus, and CENTRAL from inception through June 23, 2025, with an updated search on March 31, 2026, for randomized controlled trials comparing zonisamide to placebo in adults with AUD. The primary outcome was a reduction in alcohol use. Data were pooled using random-effects meta-analyses. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool. Findings: Five randomized controlled trials (N=344) met inclusion criteria. Zonisamide significantly reduced drinks per day (MD=−0.79; 95% CI=−0.95 to −0.63; P P P =0.11), with high heterogeneity ( I ²=91%). Zonisamide was associated with a significantly lower rate of nervousness, anxiety, or irritability (RR=0.53; 95% CI=0.34-0.84; P =0.007); other adverse events did not differ from placebo. Implications: Zonisamide reduced drinks per day and drinking days but not heavy drinking days, suggesting a selective benefit on overall consumption. A protective effect on nervousness, anxiety, and irritability was also observed, consistent with zonisamide’s GABAergic mechanism. Further well-powered trials are needed to inform clinical recommendations.Keywords
This publication has 34 references indexed in Scilit:
- Results from a randomized controlled trial of zonisamide in the treatment of alcohol use disorderJournal of Psychiatric Research, 2024
- Pharmacotherapy for Alcohol Use DisorderJAMA, 2023
- Risk‐of‐bias VISualization (robvis): An R package and Shiny web app for visualizing risk‐of‐bias assessmentsResearch Synthesis Methods, 2020
- Addictions Neuroclinical Assessment: A Neuroscience-Based Framework for Addictive DisordersBiological Psychiatry, 2016
- Pharmacotherapy for Adults With Alcohol Use Disorders in Outpatient SettingsJAMA, 2014
- Gabapentin Treatment for Alcohol DependenceJAMA Internal Medicine, 2014
- Zonisamide for Weight Loss in Obese AdultsJAMA, 2003
- Effects of zonisamide on dopaminergic systemEpilepsy Research, 1995
- Types of Alcoholics, IArchives of General Psychiatry, 1992
- An Inventory for Measuring DepressionArchives of General Psychiatry, 1961